In a five-day model the Mrp1/4 inhibitor MK571 has been demonstrated to reduce hypoxia-induced pulmonary hypertension in a dose dependent manner after daily application of 5 mg/kg or 25 mg/kg MK571 [30]. This evidence concerns the gene S100A9 and pulmonary arterial hypertension.